PhD Lucija Peterlin Mašič

PhD Lucija Peterlin Mašič
no.: 19317 source: ARIS

researcher – active in research organisation
  lucija.peterlinat signffa.uni-lj.si
  • English
  • Reading: Fluent
  • Writing: Fluent
  • Speaking: Fluent
  • German
  • Reading: Functional
  • Writing: Functional
  • Speaking: Functional
Edit
Research activity

Code Science Field Subfield
1.09.00  Natural sciences and mathematics  Pharmacy   
3.07.00  Medical sciences  Metabolic and hormonal disorders   
Keywords
Medicinal chemistry, instrumental pharmaceutical analysis, thrombne inhibitors, combinatorial chemistry, synthesis, blood coagulation
Bibliography Representative bibliographic units | Personal | COBISS+
source: COBISS
source: SICRIS
Evaluation (metodology)
Evaluation of bibliographic research performance indicators according to ARIS methodology
source: COBISS
source: ARIS
Points
954.62
A''
224.89
A'
551.46
A1/2
660.13
CI10
3,204
CImax
231
h10
31
A1
3.51
A3
0
Data for the last 5 years (citations for the last 10 years) on December 1, 2025; Data for score A3 calculation refer to period 2020-2024
Data for ARIS tenders ( 21.05.2024 – Target research programmes, archive )
Citations Citations for bibliographic records in COBIB.SI that are linked to records in citation databases
source: WoS source: Scopus source: COBISS
Database Linked records Citations Pure citations Average pure citations
WoS 116  3,903  3,349  28.87 
Scopus 119  4,316  3,704  31.13 
Mentoring junior researchers
source: ARIS
no. Name and surname Type Period Code
1 PhD Martina Durcik   Bologna doctoral studies  10/1/2018 - 9/30/2023  50490 
2 PhD Darja Gramec Skledar   Bologna doctoral studies  12/1/2012 - 10/31/2018  35432 
3 PhD Anja Fic   Bologna doctoral studies  11/1/2010 - 7/3/2014  33295 
4 PhD Tihomir Tomašić   Uniform doctoral studies  11/1/2006 - 4/30/2011  28334 
Education
source: ARIS
Level of education Professional title Study subject Faculty Year
  B. Sc.   Pharmacy  SI University of Ljubljana, Faculty of Pharmacy 1998 
Doctoral degree      SI 2003 
Doctoral dissertations and other final papers Show
Obtaining results now
source: COBISS
Employments
source: ARIS
Type of employment Research org. Research group Date of employment Position Role Title
Full time employment (120%, RD:40%)  University of Ljubljana, Faculty of Pharmacy  Chair for Pharmaceutical Chemistry  11/1/1998    Researcher  Full professor 
Research projects Legend
source: ARIS
no. Code Title Period Head
1. N1-0363  Bisphenol A substitutes: health risks to the endocrine and cardiovascular systems (Acronim: BPAsubRisk)   3/1/2024 - 2/28/2027  PhD Marija Sollner Dolenc   1,838 
2. J1-50038  New Hsp90 Inhibitor-based Therapies for Ewing Sarcoma   1/1/2024 - 12/31/2026  PhD Tihomir Tomašić   1,246 
3. J1-50023  3DfluorCO - Three-dimensional fluorine-based carbonyl bioisosteres: asymmetric synthesis and validation   10/1/2023 - 9/30/2026  PhD Andrej Emanuel Cotman   1,242 
4. J7-4635  MitoCan - Preclinical development of new Mitochondrial ion channel inhibitors for Cancer therapy   10/1/2022 - 9/30/2026  PhD Lucija Peterlin Mašič   6,828 
5. J1-3031  Development of new inhibitors of bacterial topoisomerases to overcome antimicrobial resistance   10/1/2021 - 9/30/2025  PhD Nace Zidar   1,191 
6. J1-3030  MTAvsAMR: new MultiTargeting Antibiotics against AntiMicrobial Resistance   10/1/2021 - 9/30/2025  PhD Lucija Peterlin Mašič   1,102 
7. BI-DE/23-24-009  New mitochondrial ion channels Kv1.3 inhibitors as inducers of apoptosis   1/1/2023 - 12/31/2024  PhD Lucija Peterlin Mašič   442 
8. L3-3177  Safety evaluation of cannabidiols and implications for public health and consumers behaviour   10/1/2021 - 12/31/2024  PhD Alja Štern   5,233 
9. N1-0172  Fotokemijski pristop za odkrivanje naprednih ATP-kompetitivnih prob z zaviralnim delovanjem na Topoizomerazo IIalfa (Slovene)   1/1/2021 - 12/31/2023  PhD Janez Ilaš   851 
10. J1-1717  Development of novel Hsp90 inhibitors with anticancer activity   7/1/2019 - 6/30/2023  PhD Tihomir Tomašić   2,111 
11. N1-0098  Discovery and mechanism of action of novel hEag1 potassium channel lead molecules with anti-cancer activity   1/1/2019 - 12/31/2022  PhD Lucija Peterlin Mašič   1,003 
12. J1-9192  New anticancer leads for emerging cancer target potassium ion channels hEag1 and its validation in lymphoma tumors   7/1/2018 - 6/30/2021  PhD Lucija Peterlin Mašič   2,495 
13. J1-8140  Endokrini in genotoksični potencial inhibitorjev proteinskih kinaz: pomen za tveganja za okolje in zdravje ljudi (Slovene)   5/1/2017 - 4/30/2020  PhD Metka Filipič   4,136 
14. V3-1636  Sistem odkrivanja novih psihoaktivnih snovi v Sloveniji (akronim SONDA) (Slovene)   10/1/2016 - 9/30/2018  PhD Miran Brvar   1,597 
ARIS research and infrastructure programmes Legend
source: ARIS
no. Code Title Period Head
1. P1-0208  Medicinal chemistry - drug design, synthesis and evaluation   1/1/2022 - 12/31/2027 PhD Stanislav Gobec   6,009 
2. P1-0208  Medicinal chemistry - drug design, synthesis and evaluation   1/1/2015 - 12/31/2021 PhD Stanislav Gobec   6,699 
3. P1-0208  Medicinal chemistry - drug design, synthesis and evaluation   1/1/2009 - 12/31/2014 PhD Danijel Kikelj   6,565 
4. P1-0208  Medicinal chemistry - drug design, synthesis and evaluation   1/1/2004 - 12/31/2008 PhD Danijel Kikelj   6,571 
5. P0-0502-0787  Farmacevtska kemija (Slovene)   1/1/1999 - 12/31/2003 PhD Danijel Kikelj   7,928 
International projects
no. Code Title Period Head
1. CELSA/23/031  Exploiting structural insights in IP3 receptor function to develop novel, allosteric inhibitors of IP3 receptor channels (SINFONIC)   10/1/2023 - 9/30/2025    
2. CELSA - Cental Europe Leuven Strategic Alliance-Discovery  Discovery of new leads modulating voltage gated potassium ion channels as emerging cancer targets   1/1/2017 - 12/31/2018 PhD Lucija Peterlin Mašič    
3. COST-CM1307  Targeted chemotherapy towards diseases caused by endoparasites   3/12/2014 - 3/11/2018    
4. COST-CM0801  New drugs for neglected diseases   11/28/2008 - 11/27/2012 PhD Lucija Peterlin Mašič    
Confirmation required
Views history
Favourite